136 related articles for article (PubMed ID: 35404683)
1. Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
Nitz UA; Gluz O; Kümmel S; Christgen M; Braun M; Aktas B; Lüdtke-Heckenkamp K; Forstbauer H; Grischke EM; Schumacher C; Darsow M; Krauss K; Nuding B; Thill M; Potenberg J; Uleer C; Warm M; Fischer HH; Malter W; Hauptmann M; Kates RE; Gräser M; Würstlein R; Shak S; Baehner F; Kreipe HH; Harbeck N
J Clin Oncol; 2022 Aug; 40(23):2557-2567. PubMed ID: 35404683
[TBL] [Abstract][Full Text] [Related]
2. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
Harbeck N; Nitz UA; Christgen M; Kümmel S; Braun M; Schumacher C; Potenberg J; Tio J; Aktas B; Forstbauer H; Grischke EM; Scheffen I; Malter W; von Schumann R; Just M; Zu Eulenburg C; Biehl C; Kolberg-Liedtke C; Deurloo R; de Haas S; Jóźwiak K; Hauptmann M; Kates R; Graeser M; Wuerstlein R; Kreipe HH; Gluz O;
J Clin Oncol; 2023 Aug; 41(22):3796-3804. PubMed ID: 36809046
[TBL] [Abstract][Full Text] [Related]
3. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial.
Gluz O; Kuemmel S; Nitz U; Braun M; Lüdtke-Heckenkamp K; von Schumann R; Darsow M; Forstbauer H; Potenberg J; Uleer C; Grischke EM; Aktas B; Schumacher C; Zu Eulenburg C; Kates R; Jóźwiak K; Graeser M; Wuerstlein R; Baehner R; Christgen M; Kreipe HH; Harbeck N
Ann Oncol; 2023 Jun; 34(6):531-542. PubMed ID: 37062416
[TBL] [Abstract][Full Text] [Related]
4. The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer.
Nitz U; Gluz O; Kreipe HH; Christgen M; Kuemmel S; Baehner FL; Shak S; Aktas B; Braun M; Lüdtke-Heckenkamp K; Forstbauer H; Grischke EM; Nuding B; Darsow M; Schumacher C; Krauss K; Malter W; Thill M; Warm M; Wuerstlein R; Kates RE; Harbeck N
Ther Adv Med Oncol; 2020; 12():1758835920973130. PubMed ID: 33281950
[TBL] [Abstract][Full Text] [Related]
5. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
Johnston SRD; Harbeck N; Hegg R; Toi M; Martin M; Shao ZM; Zhang QY; Martinez Rodriguez JL; Campone M; Hamilton E; Sohn J; Guarneri V; Okada M; Boyle F; Neven P; Cortés J; Huober J; Wardley A; Tolaney SM; Cicin I; Smith IC; Frenzel M; Headley D; Wei R; San Antonio B; Hulstijn M; Cox J; O'Shaughnessy J; Rastogi P;
J Clin Oncol; 2020 Dec; 38(34):3987-3998. PubMed ID: 32954927
[TBL] [Abstract][Full Text] [Related]
6. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
[TBL] [Abstract][Full Text] [Related]
7. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
Kalinsky K; Barlow WE; Gralow JR; Meric-Bernstam F; Albain KS; Hayes DF; Lin NU; Perez EA; Goldstein LJ; Chia SKL; Dhesy-Thind S; Rastogi P; Alba E; Delaloge S; Martin M; Kelly CM; Ruiz-Borrego M; Gil-Gil M; Arce-Salinas CH; Brain EGC; Lee ES; Pierga JY; Bermejo B; Ramos-Vazquez M; Jung KH; Ferrero JM; Schott AF; Shak S; Sharma P; Lew DL; Miao J; Tripathy D; Pusztai L; Hortobagyi GN
N Engl J Med; 2021 Dec; 385(25):2336-2347. PubMed ID: 34914339
[TBL] [Abstract][Full Text] [Related]
8. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
Nitz U; Gluz O; Clemens M; Malter W; Reimer T; Nuding B; Aktas B; Stefek A; Pollmanns A; Lorenz-Salehi F; Uleer C; Krabisch P; Kuemmel S; Liedtke C; Shak S; Wuerstlein R; Christgen M; Kates RE; Kreipe HH; Harbeck N;
J Clin Oncol; 2019 Apr; 37(10):799-808. PubMed ID: 30785826
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
Harbeck N; Rastogi P; Martin M; Tolaney SM; Shao ZM; Fasching PA; Huang CS; Jaliffe GG; Tryakin A; Goetz MP; Rugo HS; Senkus E; Testa L; Andersson M; Tamura K; Del Mastro L; Steger GG; Kreipe H; Hegg R; Sohn J; Guarneri V; Cortés J; Hamilton E; André V; Wei R; Barriga S; Sherwood S; Forrester T; Munoz M; Shahir A; San Antonio B; Nabinger SC; Toi M; Johnston SRD; O'Shaughnessy J;
Ann Oncol; 2021 Dec; 32(12):1571-1581. PubMed ID: 34656740
[TBL] [Abstract][Full Text] [Related]
10. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
11. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Nitz U; Gluz O; Christgen M; Kates RE; Clemens M; Malter W; Nuding B; Aktas B; Kuemmel S; Reimer T; Stefek A; Lorenz-Salehi F; Krabisch P; Just M; Augustin D; Liedtke C; Chao C; Shak S; Wuerstlein R; Kreipe HH; Harbeck N
Breast Cancer Res Treat; 2017 Oct; 165(3):573-583. PubMed ID: 28664507
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
Li L; Chang B; Jiang X; Fan X; Li Y; Li T; Wu S; Zhang J; Kariminia S; Li Q
BMC Cancer; 2018 Oct; 18(1):977. PubMed ID: 30314452
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
15. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
16. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
17. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.
Nitz U; Gluz O; Huober J; Kreipe HH; Kates RE; Hartmann A; Erber R; Moustafa Z; Scholz M; Lisboa B; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Weiss E; Böhmer S; Kreienberg R; Du Bois A; Sattler D; Thomssen C; Kiechle M; Jänicke F; Wallwiener D; Harbeck N; Kuhn W
Ann Oncol; 2014 Aug; 25(8):1551-7. PubMed ID: 24827128
[TBL] [Abstract][Full Text] [Related]
18. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
[TBL] [Abstract][Full Text] [Related]
19. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
20. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Piccart M; van 't Veer LJ; Poncet C; Lopes Cardozo JMN; Delaloge S; Pierga JY; Vuylsteke P; Brain E; Vrijaldenhoven S; Neijenhuis PA; Causeret S; Smilde TJ; Viale G; Glas AM; Delorenzi M; Sotiriou C; Rubio IT; Kümmel S; Zoppoli G; Thompson AM; Matos E; Zaman K; Hilbers F; Fumagalli D; Ravdin P; Knox S; Tryfonidis K; Peric A; Meulemans B; Bogaerts J; Cardoso F; Rutgers EJT
Lancet Oncol; 2021 Apr; 22(4):476-488. PubMed ID: 33721561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
